Tech Company Financing Transactions
InteKrin Therapeutics Funding Round
On 1/11/2007, InteKrin Therapeutics secured $23 million in funding from Sofinnova Ventures, Asset Management Ventures and OrbiMed.
Transaction Overview
Company Name
Announced On
1/11/2007
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Undisclosed
Investors
Sofinnova Ventures (Lead Investor) (James Healy)
OrbiMed (Sam Wertheimer)
Proceeds Purpose
The round will fund the clinical development of InteKrin's lead drug candidate, INT131, targeting type II diabetes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
555 Bryant St. 266
Palo Alto, CA 94301
USA
Palo Alto, CA 94301
USA
Phone
Website
Email Address
Overview
InteKrin Therapeutics, Inc. is a privately-held biopharmaceutical company based in Los Altos, CA pursuing the clinical development of therapeutics for diabetes, obesity and metabolic disorders. The company focuses on high value therapeutics addressing significant unmet medical needs in large markets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Evgeny Zaytsev
Chief Scientific Officer
David Weinstein
Browse more venture capital transactions:
Prev: 1/10/2007: AdmitOne Security venture capital transaction
Next: 1/12/2007: CA Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs